Vistagen Therapeutics (NASDAQ:VTGN) has been assigned a $4.00 price target by analysts at Maxim Group in a note issued to investors on Tuesday, TipRanks reports. The firm presently has a “buy” rating on the stock. Maxim Group’s price objective would suggest a potential upside of 277.36% from the stock’s current price.
VTGN has been the topic of a number of other reports. William Blair restated a “buy” rating on shares of Vistagen Therapeutics in a research report on Wednesday. ValuEngine upgraded shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Chardan Capital restated a “neutral” rating on shares of Vistagen Therapeutics in a research report on Monday, July 29th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $3.57.
Shares of VTGN stock traded down $0.03 during midday trading on Tuesday, reaching $1.06. 161,237 shares of the company were exchanged, compared to its average volume of 315,173. Vistagen Therapeutics has a 12 month low of $0.38 and a 12 month high of $2.32. The company has a market cap of $44.92 million, a P/E ratio of -1.18 and a beta of -0.30. The company’s 50 day moving average price is $0.96 and its two-hundred day moving average price is $0.84. The company has a debt-to-equity ratio of 2.44, a quick ratio of 2.65 and a current ratio of 2.65.
Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Vistagen Therapeutics by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,196,181 shares of the company’s stock worth $868,000 after purchasing an additional 35,729 shares in the last quarter. LPL Financial LLC bought a new stake in shares of Vistagen Therapeutics in the 2nd quarter worth approximately $27,000. Wells Fargo & Company MN bought a new stake in shares of Vistagen Therapeutics in the 2nd quarter worth approximately $31,000. HighTower Advisors LLC raised its holdings in shares of Vistagen Therapeutics by 326.3% in the 2nd quarter. HighTower Advisors LLC now owns 132,353 shares of the company’s stock worth $96,000 after purchasing an additional 101,308 shares in the last quarter. Finally, Sphera Funds Management LTD. raised its holdings in shares of Vistagen Therapeutics by 37.2% in the 1st quarter. Sphera Funds Management LTD. now owns 2,022,066 shares of the company’s stock worth $2,588,000 after purchasing an additional 548,148 shares in the last quarter. Institutional investors own 7.54% of the company’s stock.
About Vistagen Therapeutics
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Featured Article: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.